Analyst Price Targets — PVLA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 9:18 am | — | Stephens | $220.00 | $122.09 | TheFly | Palvella Therapeutics initiated with an Overweight at Stephens |
| February 24, 2026 7:33 pm | — | Truist Financial | $210.00 | $120.41 | TheFly | Palvella Therapeutics price target raised to $210 from $190 at Truist |
| February 24, 2026 6:49 pm | — | Chardan Capital | $210.00 | $118.61 | TheFly | Palvella Therapeutics price target raised to $210 from $174 at Chardan |
| February 24, 2026 4:25 pm | — | Stifel Nicolaus | $250.00 | $119.26 | TheFly | Palvella Therapeutics price target raised to $250 from $180 at Stifel |
| February 24, 2026 3:08 pm | — | H.C. Wainwright | $255.00 | $116.66 | TheFly | Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright |
| January 7, 2026 10:53 am | — | Mizuho Securities | $205.00 | $90.43 | TheFly | Palvella Therapeutics initiated with an Outperform at Mizuho |
| December 16, 2025 11:57 am | Whitney Ijem | Canaccord Genuity | $204.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $204 from $148 at Canaccord |
| December 16, 2025 11:54 am | Ryan Deschner | Raymond James | $193.00 | $91.51 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $193 at Raymond James |
| December 15, 2025 9:21 pm | — | Chardan Capital | $174.00 | $88.42 | TheFly | Palvella Therapeutics price target raised to $174 from $110 at Chardan |
| December 15, 2025 8:02 pm | Jeff Mukherjee | BTIG | $192.00 | $88.42 | StreetInsider | Palvella Therapeutics (PVLA) PT Raised to $192 at BTIG |
Latest News for PVLA
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted
4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share. This was a derivative transaction involving the exercise and immediate sale of options.
FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted
Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PVLA.
U.S. House Trading
No House trades found for PVLA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.